Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The immune checkpoint inhibitors: where are we now?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Major-market sales of select immune checkpoint inhibitors (estimated).


  1. Decision Resources Group: Malignant Melanoma. Pharmacor Service. Onkos. 2013–2014.

  2. Decision Resources Group: NSCLC. Pharmacor Service. Onkos. 2013–2014.

  3. Decision Resources Group: Pharmaview Service. 2014.

  4. Decision Resources Group: Immunotherapies. Pharmacor Service. Onkos. 2014.

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Rachel M. Webster.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Webster, R. The immune checkpoint inhibitors: where are we now?. Nat Rev Drug Discov 13, 883–884 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing